NASA shuts down $2 billion satellite refueling project after Maxar is cited for poor performance

NASA shuts down  billion satellite refueling project after Maxar is cited for poor performance


A “grapple test” of the spacecraft’s robotic servicing arm.

NASA

NASA is shutting down a $2 billion project to test satellite refueling in space, it announced on Friday, after the agency’s auditor criticized the program’s lead contractor Maxar for poor performance.

The space agency said in a statement that the OSAM-1, or “On-orbit Servicing, Assembly, and Manufacturing 1,” project was being discontinued after nearly a decade of work.

NASA cited “continued technical, cost, and schedule challenges, and a broader community evolution away from refueling unprepared spacecraft, which has led to a lack of a committed partner” in a statement.

“While we are disappointed by the decision to discontinue the program, we are committed to supporting NASA in pursuing potential new partnerships or alternative hardware uses as they complete the shutdown,” Maxar Space Systems spokesperson Eric Glass said in a statement to CNBC.

NASA did not respond to CNBC’s request for comment on how many personnel will be impacted as a result of OSAM-1’s cancellation.

Maxar was taken private by private equity firm Advent International in May 2023 before being split into two businesses – Maxar Intelligence, focused on satellite imagery and analytics, and Maxar Space Systems, focused on spacecraft manufacturing.

Sign up here to receive weekly editions of CNBC’s Investing in Space newsletter.

NASA’s Goddard center in Maryland was leading the work on OSAM-1, with Maxar Space Systems as the project’s prime contractor under multiple deals. OSAM-1 has been in development since 2015, with the goal of docking with the U.S.-owned Landsat 7 imagery satellite in orbit, to repair and refuel the aging spacecraft to extend its life.

But OSAM-1 has fallen years behind schedule, while the program’s cost to NASA soared. In a scathing October report, NASA’s Inspector General “found that project cost increases and schedule delays were primarily due to the poor performance of Maxar,” while noting that the agency’s Goddard center has also struggled with key parts of development.

“NASA and Maxar officials acknowledged that Maxar underestimated the scope and complexity of the work, lacked full understanding of NASA technical requirements, and were deficient in necessary expertise,” NASA’s Inspector General said in its report, following a year-long audit.

The agency’s auditor noted that OSAM-1 was likely to both “exceed its current $2.05 billion price tag and the December 2026 launch date,” which was already six years behind schedule. The report, citing Maxar representatives, noted the company was “no longer profiting from their work on OSAM-1” and, in NASA’s view, no longer appeared “to be a high priority for Maxar in terms of the quality of its staffing.”

NASA’s cancellation of OSAM-1 comes months after Maxar delivered major segments of the spacecraft to Goddard in Maryland – but other key parts were yet to be finished.

Satellite servicing is a nascent sub-sector of the space industry that’s only recently begun to be proven out, with Northrop Grumman’s extension missions representing an early effort.

Here's why the U.S., China, India, Japan and others are rushing back to the moon



Source

Hershey says GLP-1s are driving higher gum and mint sales
Business

Hershey says GLP-1s are driving higher gum and mint sales

Packages of Ice Breakers spearmint mints Mints are displayed at a Costco Wholesale store on April 27, 2025 in San Diego, California. Kevin Carter | Getty Images Hershey is seeing higher sales for its mints and gum — thanks to the growing use of GLP-1 drugs. “We’ve also seen strong demand for gum and mints, […]

Read More
More than 20,000 people are taking Eli Lilly’s weight loss pill Foundayo, CEO says
Business

More than 20,000 people are taking Eli Lilly’s weight loss pill Foundayo, CEO says

More than 20,000 people have started taking Eli Lilly‘s GLP-1 pill Foundayo in its first few weeks on the market, Lilly CEO Dave Ricks told CNBC on Thursday. The FDA approved Lilly’s once-daily pill Foundayo earlier this month, making it the second oral GLP-1 drug behind Novo Nordisk’s Wegovy pill. Investors have been closely tracking […]

Read More
Lawyers to the wealthy warn that AI legal advice comes with serious risks
Business

Lawyers to the wealthy warn that AI legal advice comes with serious risks

Displeased couple having problems during a meeting with their agent in the office. Skynesher | E+ | Getty Images A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Lawyer Tasha Dickinson said […]

Read More